journal
MENU ▼
Read by QxMD icon Read
search

Bladder Cancer

journal
https://www.readbyqxmd.com/read/28035330/checkpoint-inhibitors-for-advanced-bladder-cancer
#1
Edward M Messing
No abstract text is available yet for this article.
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035329/clinical-trials-corner
#2
Piyush K Agarwal, Cora N Sternberg
No abstract text is available yet for this article.
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035328/bladder-cancer-screening-in-lebanese-population-there-is-nothing-more-unequal-than-the-equal-treatment-of-unequal-people
#3
Mohammed Shahait, Muhammad Bulbul
Bladder cancer screening has been perplexing the uro-oncological community for the last decade. In this commentary, we ruminate on the feasibility of bladder cancer screening in our population based on epidemiological proponents.
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035327/challenging-cases-in-urothelial-cancer
#4
Mark S Soloway
No abstract text is available yet for this article.
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035326/the-new-immortalized-uroepithelial-cell-line-hblak-contains-defined-genetic-aberrations-typical-of-early-stage-urothelial-tumors
#5
Michèle J Hoffmann, Evangelia Koutsogiannouli, Margaretha A Skowron, Maria Pinkerneil, Günter Niegisch, Artur Brandt, Stefanie Stepanow, Harald Rieder, Wolfgang A Schulz
Background: Cell culture models of normal urothelial cells are important for studying differentiation, disease mechanisms and anticancer drug development. Beyond primary cultures with their limitations in lifespan, interindividual heterogeneity and supply, few conditionally immortalized cell lines with limited applicability due to partial transformation or impaired differentiation capacity are available. We describe characteristics of the new spontaneously immortalized cell line HBLAK derived from a primary culture of uroepithelial cells...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035325/effect-of-neoadjuvant-chemotherapy-on-renal-function-following-radical-cystectomy-is-there-a%C3%A2-meaningful-impact
#6
Thenappan Chandrasekar, Neil Pugashetti, Blythe Durbin-Johnson, Marc A Dall'Era, Christopher P Evans, Ralph W deVere White, Stanley A Yap
Objective: To evaluate the patterns of impact of neoadjuvant chemotherapy (NAC) on renal function across the initial year following treatment for muscle-invasive bladder cancer (MIBC) with radical cystectomy (RC). Methods: We reviewed the charts of 241 patients who underwent RC for urothelial carcinoma of the bladder between 2003-14 at our institution. Renal function was evaluated at multiple time points (pre-chemotherapy, pre-operatively, post-operatively, 6-12 months follow-up), and then classified by CKD staging...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035324/the-july-effect-in-radical-cystectomy-mortality-morbidity-and-efficiency
#7
Keegan Zuk, Derek Jensen, Jessie Gills, Hadley Wyre, Jeffrey M Holzbeierlein, Ernesto Lopez-Corona, Eugene K Lee
Background: The "July effect" is the potential effect that new and recently promoted residents have on patient care during the first months of the academic year. Literature suggests that the July effect may worsen patient outcomes and lead to systemic inefficiencies. Objective: We evaluate the July effect on mortality, morbidity, and efficiency outcomes in patients undergoing radical cystectomy. Methods: A chart review was performed in patients who underwent radical cystectomy between January 2008 and April 2012...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035323/the-role-of-pd-l1-expression-and%C3%A2-intratumoral-lymphocytes-in%C3%A2-response%C3%A2-to-perioperative-chemotherapy%C3%A2-for-urothelial-carcinoma
#8
F Erlmeier, A K Seitz, G Hatzichristodoulou, L Stecher, M Retz, J E Gschwend, W Weichert, H R Kübler, T Horn
Introduction: Immunological pathways are relevant for the effectiveness of conventional cytotoxic chemotherapy. Recently, checkpoint inhibition of the PD-1/PD-L1 axis has been shown to be therapeutically relevant in urothelial carcinoma. Objective: To monitor PD-L1 expression on tumor cells and intratumoral infiltration with CD8 positive lymphocytes during perioperative chemotherapy for urothelial cancer and to evaluate their use as potential predictive markers for chemotherapy. Patients and Methods: Sixty-four patients with muscle-invasive urothelial cancer were included in the analysis...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035322/micropapillary-bladder-cancer-insights-from-the-national-cancer-database
#9
Wilson Sui, Justin T Matulay, Maxwell B James, Ifeanyi C Onyeji, Marissa C Theofanides, Arindam RoyChoudhury, G Joel DeCastro, Sven Wenske
Introduction: Micropapillary bladder cancer (MPBC) is a variant histology of urothelial carcinoma (UC) that is associated with poor outcomes however given its rarity, little is known outside of institutional reports. We sought to use a population-level cancer database to assess survival outcomes in patients treated with surgery, radiation therapy and/or chemotherapy. Materials and Methods: The National Cancer Database (NCDB) was queried for all cases of MPBC and UC using International Classification of Disease-O-3 morphologic codes between 2004-2014...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035321/patterns-of-bladder-preservation-therapy%C3%A2-utilization-for-muscle-invasive-bladder-cancer
#10
Tracy L Rose, Allison M Deal, Sylvain Ladoire, Gilles Créhange, Matthew D Galsky, Jonathan E Rosenberg, Joaquim Bellmunt, Akhila Wimalasingham, Yu-Ning Wong, Lauren C Harshman, Simon Chowdhury, Guenter Niegisch, Michalis Liontos, Evan Y Yu, Sumanta K Pal, Ronald C Chen, Andrew Z Wang, Matthew E Nielsen, Angela B Smith, Matthew I Milowsky
Background: Trimodality bladder preservation therapy (BPT) in muscle invasive bladder cancer (MIBC) includes a maximal transurethral resection followed by concurrent chemoradiotherapy as an alternative to radical cystectomy (RC) in appropriately selected patients, or as a treatment option in non-cystectomy candidates. Several chemotherapy regimens can be used in BPT, but little is known about current practice patterns. Objective: To describe utilization patterns of BPT and associated survival outcomes in MIBC...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035320/clinical-significance-of-early-changes-in%C3%A2-circulating-tumor-cells-from-patients-receiving-first-line-cisplatin-based-chemotherapy-for-metastatic-urothelial-carcinoma
#11
Emanuela Fina, Andrea Necchi, Patrizia Giannatempo, Maurizio Colecchia, Daniele Raggi, Maria Grazia Daidone, Vera Cappelletti
Background: The therapeutic paradigm of metastatic urothelial carcinoma (UC) is rapidly shifting and new biomarkers are needed to enhance patient selection. Objective: Early identification of dynamic predictors of outcome may be a key to optimize the sequence of effective therapies in metastatic UC patients. Methods: Blood samples from patients receiving first-line MVAC chemotherapy were collected at baseline (T0) and after 2 cycles (T2). Samples were processed by immunomagnetic beads (AdnaTest ProstateCancerSelect kit) and the expression of EPCAM, MUC1 and ERBB2 was studied using multiplex-PCR...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035319/the-role-of-transurethral-resection-in%C3%A2-trimodal-therapy-for-muscle-invasive-bladder-cancer
#12
REVIEW
Christopher M Russell, Amir H Lebastchi, Tudor Borza, Daniel E Spratt, Todd M Morgan
While radical cystectomy (RC) with pelvic lymph node dissection (PLND) represents the accepted gold standard for the treatment of muscle-invasive bladder cancer, this treatment approach is associated with significant morbidity. As such, bladder preservation strategies are often utilized in patients who are either deemed medically unfit due to significant comorbidities or whom decline management with RC and PLND secondary to its associated morbidity. In a select group of patients, meeting strict criteria, bladder preservation approaches may be employed with curative intent...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/28035318/circulating-biomarkers-in-bladder-cancer
#13
REVIEW
Lakshminarayanan Nandagopal, Guru Sonpavde
Bladder cancer is a molecularly heterogeneous disease characterized by multiple unmet needs in the realm of diagnosis, clinical staging, monitoring and therapy. There is an urgent need to develop precision medicine for advanced urothelial carcinoma. Given the difficulty of serial analyses of metastatic tumor tissue to identify resistance and new therapeutic targets, development of non-invasive monitoring using circulating molecular biomarkers is critically important. Although the development of circulating biomarkers for the management of bladder cancer is in its infancy and may currently suffer from lower sensitivity of detection, they have inherent advantages owing to non-invasiveness...
October 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/27500203/clinical-trials-corner
#14
(no author information available yet)
No abstract text is available yet for this article.
July 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/27500196/the-future-of-intravesical-drug-delivery-for%C3%A2-non-muscle-invasive-bladder-cancer
#15
REVIEW
Laura Douglass, Mark Schoenberg
Despite being the fifth most common cancer in the United States, minimal progress has been made in the treatment of bladder cancer in over a decade. Intravesical instillation of Bacillus Calmette-Guerin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC) has been in use for over 30 years and remains the standard treatment in cases of intermediate and high risk disease. Despite the relative success of intravesical BCG, unmet needs in the treatment of NMIBC persist. These challenges include disease recurrence and progression even with treatment with BCG, as well as issues regarding its availability and patient tolerability...
July 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376147/clinical-trials-corner
#16
(no author information available yet)
No abstract text is available yet for this article.
April 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376146/the-impact-of-blue-light-cystoscopy-with-hexaminolevulinate-hal-on-progression-of-bladder-cancer-a-new-analysis
#17
Ashish M Kamat, Michael Cookson, J Alfred Witjes, Arnulf Stenzl, H Barton Grossman
Background: The International Bladder Cancer Group (IBCG) recently proposed a new definition of disease progression in non-muscle invasive bladder cancer (NMIBC), including change in T-stage, change to T2 or higher or change from low to high grade. Objective: To establish whether blue light cystoscopy with hexaminolevulinate (HAL) impacts the rate of progression and time to progression using the revised definition. Methods: An earlier long-term follow-up of a controlled Phase III study reported outcomes following blue light cystoscopy with HAL (255 patients) or white light (WL) cystoscopy (261 patients) in NMIBC patients...
April 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376145/benefit-of-adjuvant-chemotherapy-and-pelvic-lymph-node-dissection-in-pt3-and-node-positive-bladder-cancer-patients-treated-with-radical-cystectomy
#18
Peter J Boström, Tuomas Mirtti, Bas van Rhijn, Neil E Fleshner, Antonio Finelli, Matti Laato, Michael A Jewett, Malcom J Moore, Srikala Sridhar, Martti Nurmi, Ian F Tannock, Alexandre R Zlotta
Background: Benefits of adjuvant chemotherapy (AC) and extent of pelvic lymph node dissection (PLND) in radical cystectomy (RC) are debated. Results from randomized trials are still expected. Objective: To analyze the effects of AC and PLND in two academic centers with opposite policies regarding their use. Methods: 581 bladder cancer patients who underwent RC without neoadjuvant chemotherapy, from Toronto (University Health Network), Canada, and Turku University Hospital, Finland were included. Disease specific survival (DSS) and failure patterns were assessed...
April 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376138/summary-and-recommendations-from-the-national-cancer-institute-s-clinical-trials-planning-meeting-on-novel-therapeutics-for-non-muscle-invasive-bladder-cancer
#19
Seth P Lerner, Dean F Bajorin, Colin P Dinney, Jason A Efstathiou, Susan Groshen, Noah M Hahn, Donna Hansel, David Kwiatkowski, Michael O'Donnell, Jonathan Rosenberg, Robert Svatek, Jeffrey S Abrams, Hikmat Al-Ahmadie, Andrea B Apolo, Joaquim Bellmunt, Margaret Callahan, Eugene K Cha, Charles Drake, Jonathan Jarow, Ashish Kamat, William Kim, Margaret Knowles, Bhupinder Mann, Luigi Marchionni, David McConkey, Lisa McShane, Nilsa Ramirez, Andrew Sharabi, Arlene H Sharpe, David Solit, Catherine M Tangen, Abdul Tawab Amiri, Eliezer Van Allen, Pamela J West, J A Witjes, Diane Zipursky Quale
The NCI Bladder Cancer Task Force convened a Clinical Trials Planning Meeting (CTPM) Workshop focused on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (NMIBC). Meeting attendees included a broad and multi-disciplinary group of clinical and research stakeholders and included leaders from NCI, FDA, National Clinical Trials Network (NCTN), advocacy and the pharmaceutical and biotech industry. The meeting goals and objectives were to: 1) create a collaborative environment in which the greater bladder research community can pursue future optimally designed novel clinical trials focused on the theme of molecular targeted and immune-based therapies in NMIBC; 2) frame the clinical and translational questions that are of highest priority; and 3) develop two clinical trial designs focusing on immunotherapy and molecular targeted therapy...
April 27, 2016: Bladder Cancer
https://www.readbyqxmd.com/read/27376135/effects-of-androgen-and-estrogen-receptor-signaling-pathways-on-bladder-cancer-initiation-and-progression
#20
REVIEW
Guilherme Godoy, Georgios Gakis, Carolyn L Smith, Omar Fahmy
Epidemiologic studies have long demonstrated clear differences in incidence and progression of bladder cancer between genders suggesting that the mechanisms of development and progression in these tumors have a strong association with steroid hormonal pathways. Such observations led to preclinical studies investigating the role of androgen and estrogen receptors, as well as their cognate hormones in bladder cancer initiation and progression. Using various in vitro cell line assays and in vivo mouse models, studies have elucidated different mechanisms and signaling pathways through which these steroid receptors may participate in this disease...
April 27, 2016: Bladder Cancer
journal
journal
52783
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"